DNA vaccines.
Preclinical DNA vaccine development has continued apace during the past year, with the investigation of several new infectious and non-infectious disease targets as well as advances in our understanding of some of the basic immunologic mechanisms, such as effector cells, responsible for conferring protection. The coming year promises to be at least as exciting, as initial human clinical studies have begun.
Ulmer
J B
JB
Department of Virus & Cell Biology, Merck Research Laboratories, WP 16-101, West Point, PA 19486, USA. jeff_ulmer@merck.com
Sadoff
J C
JC
Liu
M A
MA
D000818:Animals; D004247:DNA / Q000276:immunology*; D006801:Humans; D014614:Vaccines, Synthetic / Q000276:immunology*
D014614:Vaccines, Synthetic; D004247:DNA